%K Alzheimer's disease, amyloid beta, biomarkers, cerebrovascular disease, non-Alzheimer's pathophysiology, phosphorylated tau, plasma
%J Alzheimer's & Dementia
%L discovery10126218
%O This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
%C United States
%X INTRODUCTION: There is increasing evidence that phosphorylated tau (P-tau181) is a specific biomarker for Alzheimer's disease (AD) pathology, but its potential utility in non-White patient cohorts and patients with concomitant cerebrovascular disease (CeVD) is unknown. METHODS: Single molecule array (Simoa) measurements of plasma P-tau181, total tau, amyloid beta (Aβ)40 and Aβ42, as well as derived ratios were correlated with neuroimaging modalities indicating brain amyloid (Aβ+), hippocampal atrophy, and CeVD in a Singapore-based cohort of non-cognitively impaired (NCI; n = 43), cognitively impaired no dementia (CIND; n = 91), AD (n = 44), and vascular dementia (VaD; n = 22) subjects. RESULTS: P-tau181/Aβ42 ratio showed the highest area under the curve (AUC) for Aβ+ (AUC = 0.889) and for discriminating between AD Aβ+ and VaD Aβ- subjects (AUC = 0.903). In addition, P-tau181/Aβ42 ratio was associated with hippocampal atrophy. None of the biomarkers was associated with CeVD. DISCUSSION: Plasma P-tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD.
%N 10
%T Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease
%A JR Chong
%A NJ Ashton
%A TK Karikari
%A T Tanaka
%A FN Saridin
%A A Reilhac
%A EG Robins
%A Y-H Nai
%A H Vrooman
%A S Hilal
%A H Zetterberg
%A K Blennow
%A MKP Lai
%A CP Chen
%V 17
%D 2021
%P 1649-1662